Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
暂无分享,去创建一个
T. Bosse | E. M. van der Steen-Banasik | V. Smit | I. Jürgenliemk-Schulz | G. Ortoft | R. Nout | E. Høgdall | C. Høgdall | J. Mens | C. Creutzberg | J. Jobsen | L. Lutgens | E. Peters | A. León-Castillo | M. Boennelycke | A. Léon-Castillo
[1] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[2] K. Mertz,et al. Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer , 2020, Cancer Immunology Research.
[3] J. Marcickiewicz,et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer – a Swedish Gynecologic Cancer Group (SweGCG) study , 2019, Acta oncologica.
[4] C. Genestie,et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer , 2019, Histopathology.
[5] C. Høgdall,et al. Location of recurrences in high-risk stage Iendometrial cancer patients not given postoperative radiotherapy: A Danish gynecological cancer group study , 2019, International Journal of Gynecologic Cancer.
[6] T. Bosse,et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. , 2018, Gynecologic oncology.
[7] E. Pollom,et al. Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma. , 2017, Gynecologic oncology.
[8] C. Sessa,et al. Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] M. Stockler,et al. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial , 2016, British Journal of Cancer.
[10] T. Bosse,et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.
[11] C. Høgdall,et al. Valid and complete data on endometrial cancer in the Danish Gynaecological Cancer Database. , 2014, Danish medical journal.
[12] H. Kitchener,et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. , 2012, Journal of the National Cancer Institute.
[13] H. Putter,et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.
[14] N. Yaegashi,et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. , 2009, Gynecologic oncology.
[15] H. Boezen,et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.
[16] M. Maiman,et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.
[17] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .
[18] T. Kawarabayashi,et al. The grading of lymphovascular space invasion in endometrial carcinoma , 1999, Cancer.
[19] C. Morrow,et al. Relationship between surgical‐pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study , 1991, Gynecologic oncology.
[20] P. Goodfellow,et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.